TORONTO (October 14, 2010) – Of the approximately 300 million people around the world who are diabetics, 45 million of them develop foot ulcers that bleed – and the infection from those ulcers can spread.
Working to halt this is Dr. Ping Lee, a professor at the University of Toronto’s (U of T) Leslie Dan Faculty of Pharmacy and GlaxoSmithKline chair in Pharmaceutics and Drug Delivery. He and his team have created a new sustained‐release form of nitric oxide (NO) that can not only stop the infections at wound sites, but also has the potential to speed up wound‐healing.
Still, the technology may have stayed on the shelf, even with three years worth of data demonstrating therapeutic relevance. The ultimate success of the technology is due to an effective collaboration between Dr. Lee, the Innovations and Partnerships Office (IPO) at U of T and MaRS Innovation (MI). Lee worked with IPO and MI to formulate a development plan in consultation with numerous industry advisors.